ArticleCell communication and signaling : CCS2026
IL-15 promotes immune escape, invasion, and metastasis of pancreatic cancer by upregulating PD-L1 expression via the JAK1/STAT1/IRF1 pathway.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The expression of Programmed Death-Ligand 1 (PD-L1) in tumor cells is regulated by multiple factors, and this expression further affects the immune function of the microenvironment. However, the effect of Interleukin 15 (IL-15) cytokine on PD-L1 expression in pancreatic cancer and its related mechanisms remain unclear. Bioinformatics databases suggest a close correlation between IL-15 and PD-L1. WB, qPCR, and flow cytometry experiments confirmed that IL-15 upregulates PD-L1 expression in pancreatic cancer cells. A co-culture model of pancreatic cancer cells and Peripheral Blood Mononuclear Cells (PBMCs) was established. Carboxyfluorescein Succinimidyl Ester (CFSE) labeling, intracellular flow cytometry staining, ELISA, and Lactate Dehydrogenase (LDH) release assay confirmed that IL-15 inhibits the proliferation, activation, cytokine secretion, and tumor-killing ability of CD8 + T cells in co-cultured PBMCs. Wound healing and Transwell assays showed that IL-15 enhances the migration and invasion abilities of pancreatic cancer cells in the co-culture system. However, PD-L1 neutralizing antibody (anti-PD-L1) reversed IL-15-induced immunosuppression, as well as the enhanced migration and invasion of pancreatic cancer cells caused by IL-15. Further WB experiments revealed that IL-15 upregulates PD-L1 expression in pancreatic cancer cells via the JAK1/STAT1/IRF1 axis, and Fludarabine reversed IL-15-induced immunosuppression and tumor migration/invasion. In animal experiments, immunofluorescence staining, in vivo small animal imaging, and HE staining demonstrated that IL-15 upregulates PD-L1 expression in pancreatic cancer, promotes tumor growth and metastasis, and inhibits tumor immune function. Thus, we conclude that IL-15 upregulates PD-L1 expression via the JAK1/STAT1/IRF1 axis, thereby promoting immune escape, invasion, and metastasis of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.